Learn More About CMT Research
Find a CMTA Center of Excellence
Get Involved with our Youth Program
Participate in a CMTA Event

CMTA News

CMTA invests $423K in genomic research to close CMT diagnostic gaps, advance gene discovery, and expand the GENESIS platform, driving progress toward a cure.

CMTA Invests $423K to Accelerate CMT Diagnostics and Gene Discovery

Read More

Episode 2 of the Simply CMT Podcast with Jonah Berger

Simply CMT Podcast Episode 2: Jonah Berger

Read More

CMTA-STAR Partner Alesta

Encouraging News in CMT Research from CMTA-STAR Alliance Partner Alesta Therapeutics

Read More

CMTA’s New Video Aims to Increase Awareness About CMT

Read More

Nervosave: Shaping the Future of Genetic Therapy for CMT1A

Nervosave: Shaping the Future of Genetic Therapy for CMT1A

Read More

CMTA 2024 Year in Review: Accelerating Research, Empowering Patients

CMTA 2024 Year in Review Magazine

Read More

CMTA Invests $423K to Accelerate CMT Diagnostics and Gene Discovery

Encouraging News in CMT Research from CMTA-STAR Alliance Partner Alesta Therapeutics

Nervosave: Shaping the Future of Genetic Therapy for CMT1A

CMTA-STAR Alliance Partner NMD Pharma Announces FDA Orphan Drug Designation for NMD670

CMTA-STAR Alliance Partner NMD Pharma Publishes Transformative Study on Charcot-Marie-Tooth Disease

CMTA-STAR Collaboration Celebrates a Decade of CMT Genetic Discovery Through the GENESIS Database

Alliance Partner NMD Pharma A/S Launches Phase II SYNAPSE-CMT Trial with First Patient Dosed at CMTA Center of Excellence

CMTA-INC Strategic Alliance Announces the 2025 Inherited Neuropathy Fellowship

Accelerating Research. Empowering Patients.

CMT The Greeves Family

Accelerating Research

Nearly $30 million invested in CMTA-STAR to support research projects for all CMT types.

Our Research

Empowering Patients

CMTA actively works to improve the quality of life for all CMT-affected families.

Living with CMT